Core Viewpoint - The announcement by the company indicates that three of its products have been included in the National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Directory, which is expected to positively impact future performance [1] Group 1: Product Inclusion - The company has three products included in the new drug directory: injectable aripiprazole microspheres, which is included for the first time; injectable triptorelin acetate microspheres, which has a new indication; and injectable esomeprazole sodium, which has successfully renewed its contract [1] - No products from the company have been removed from the directory, indicating a stable product portfolio [1] Group 2: Market Impact - The inclusion of these products is expected to expand market reach and improve drug accessibility, which will likely have a positive effect on the company's future performance [1] - The new directory will be implemented on January 1, 2026, and is not expected to have a significant impact on the current period's performance [1]
丽珠医药：3个产品纳入2025年国家医保目录